MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Allogene Therapeutics Inc

Chiusa

SettoreSettore sanitario

1.15 -1.71

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.13

Massimo

1.21

Metriche Chiave

By Trading Economics

Entrata

206K

-60M

EPS

-0.28

Margine di Profitto

272,450

Dipendenti

226

EBITDA

-302K

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+637.82% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.2M

258M

Apertura precedente

2.86

Chiusura precedente

1.15

Notizie sul Sentiment di mercato

By Acuity

50%

50%

143 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 lug 2025, 15:29 UTC

I principali Market Mover

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 lug 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 lug 2025, 23:44 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 lug 2025, 23:41 UTC

Discorsi di Mercato

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 lug 2025, 23:19 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 lug 2025, 23:19 UTC

Discorsi di Mercato

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 lug 2025, 22:20 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 lug 2025, 22:20 UTC

Discorsi di Mercato

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 lug 2025, 21:34 UTC

Acquisizioni, Fusioni, Takeovers

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 lug 2025, 20:45 UTC

Acquisizioni, Fusioni, Takeovers

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 lug 2025, 20:16 UTC

Discorsi di Mercato

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 lug 2025, 19:37 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 lug 2025, 19:12 UTC

Discorsi di Mercato

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 lug 2025, 18:33 UTC

Discorsi di Mercato

Gold Flat as Investors Assess Market Direction -- Market Talk

7 lug 2025, 18:27 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 lug 2025, 16:53 UTC

Utili

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 lug 2025, 16:30 UTC

Discorsi di Mercato

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 lug 2025, 16:05 UTC

Acquisizioni, Fusioni, Takeovers

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 lug 2025, 15:41 UTC

Discorsi di Mercato

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 lug 2025, 15:41 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

7 lug 2025, 15:40 UTC

Discorsi di Mercato

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 lug 2025, 15:30 UTC

Discorsi di Mercato

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 lug 2025, 15:18 UTC

Discorsi di Mercato

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 lug 2025, 15:14 UTC

Acquisizioni, Fusioni, Takeovers

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 lug 2025, 15:00 UTC

Acquisizioni, Fusioni, Takeovers

GSK Completes Acquisition of Efimosfermin

7 lug 2025, 14:52 UTC

Discorsi di Mercato

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 lug 2025, 14:51 UTC

Discorsi di Mercato

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 lug 2025, 14:45 UTC

Discorsi di Mercato

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Confronto tra pari

Modifica del prezzo

Allogene Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

637.82% in crescita

Previsioni per 12 mesi

Media 8.78 USD  637.82%

Alto 14 USD

Basso 4 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

11

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.18 / 1.69Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

143 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.